Related Experiment Video
Updated: Jun 6, 2025
Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Amoebicidal and cysticidal in vitro activity of cationic dendritic molecules against Acanthamoeba polyphaga and
Cristina Verdú-Expósito1, Tania Martín-Pérez2, Jorge Pérez-Serrano2
1University of Alcala, Department of Biomedicine and Biotechnology, 28805, Madrid, Spain. cristina.verdu@uah.es.
Abstract:
Acanthamoeba species are responsible for serious human infections, including Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). These pathogens have a simple life cycle consisting of an infective trophozoite stage and a resistant cyst stage, with cysts posing significant treatment challenges due to their resilience against harsh conditions and chemical agents. Current treatments for AK often involve combining diamines, such as propamidine, and biguanides, such as chlorhexidine (CLX), which exhibit limited efficacy and significant toxicity. Thus, the effect of new therapeutic molecules, such as multifunctional systems (e.g., carbosilane dendritic molecules), should be studied as potential alternatives due to their biocidal properties and lower toxicity. This study evaluates various dendritic compounds against trophozoites and cysts of two Acanthamoeba clinical isolates, both alone and in combination with CLX, and assesses their cytotoxicity on HeLa cells. The results indicated that certain dendritic compounds, especially BDSQ024, were effective against both trophozoites and cysts. Additionally, combinations of dendritic molecules and CLX showed enhanced efficacy in eliminating trophozoites and cysts, suggesting potential for synergistic treatments. The study underscores the promise of dendritic molecules in developing more effective and less toxic therapies for Acanthamoeba infections.
Insights
New dendritic molecules show promise for treating Acanthamoeba infections, including Acanthamoeba keratitis. These compounds, especially BDSQ024, are effective against both parasite stages and may offer a less toxic alternative to current therapies.
Area of Science:
- Microbiology
- Parasitology
- Drug Discovery
Background:
- Acanthamoeba species cause severe human infections like Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE).
- Acanthamoeba cysts are highly resistant to existing treatments, posing a significant therapeutic challenge.
- Current AK treatments, like propamidine and chlorhexidine (CLX), have limited efficacy and considerable toxicity.
Purpose of the Study:
- To evaluate the efficacy of novel dendritic compounds against Acanthamoeba trophozoites and cysts.
- To assess the synergistic potential of combining dendritic molecules with chlorhexidine (CLX).
- To determine the cytotoxicity of these dendritic compounds on human cells.
Main Methods:
- Testing various dendritic compounds against Acanthamoeba clinical isolates (trophozoites and cysts).
- Evaluating dendritic compounds alone and in combination with chlorhexidine (CLX).
- Assessing cytotoxicity using HeLa cells.
Main Results:
- Specific dendritic compounds, notably BDSQ024, demonstrated effectiveness against both Acanthamoeba trophozoites and cysts.
- Combinations of dendritic molecules and CLX exhibited enhanced efficacy in eliminating Acanthamoeba.
- The tested dendritic compounds showed low cytotoxicity on HeLa cells.
Conclusions:
- Dendritic molecules represent a promising new class of therapeutic agents for Acanthamoeba infections.
- Combinations of dendritic molecules and CLX offer a potential strategy for synergistic and more effective treatments.
- These findings suggest a pathway towards developing safer and more potent therapies for challenging Acanthamoeba infections.
More Related Videos
07:33Author Spotlight: Studying Behavior of Acanthamoeba to Develop Targeted Strategies for Preventing Acanthamoeba Keratitis
Published on: September 20, 2024
08:54Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
